Cervical cancer screening guidelines have been updated by the American Cancer Society (ACS), placing a greater emphasis on testing for the human papillomavirus (HPV) – the virus responsible for nearly all cases of the disease – and, significantly, approving the use of self-collected samples for testing. These new recommendations, applicable to anyone with a cervix at average risk, aim to improve access to screening and reduce cervical cancer rates, which remain a concern despite decades of progress. Understanding these changes in cervical cancer screening is crucial for informed healthcare decisions.
The ACS is one of two leading organizations providing guidance on cancer screening; the other is the U.S. Preventive Services Task Force (USPSTF). While both groups aim to reduce cancer incidence and mortality, their recommendations can differ, impacting what health insurance plans cover. The USPSTF is currently revising its own cervical cancer screening guidelines, meaning further changes may be on the horizon. Currently, the USPSTF recommends Pap tests for women ages 21 to 29, transitioning to HPV primary testing or co-testing at age 30, a difference from the ACS’s recommendation to begin screening at age 25 regardless of the test used.
What the New ACS Guidelines Recommend
A core shift in the ACS guidelines is the prioritization of “HPV primary” testing. This approach directly looks for the presence of high-risk HPV types known to cause cervical cancer. If HPV primary testing isn’t available, the ACS recommends “co-testing,” which combines an HPV test with a Pap test (too known as cytology). If neither of those options are available, a Pap test alone is still considered acceptable. The ACS emphasizes that the goal is to identify HPV infection early, as it often precedes cellular changes that can lead to cancer.
One of the most significant changes is the acceptance of self-collected HPV tests. Traditionally, samples for both HPV and Pap tests were collected by a healthcare provider during a pelvic exam. While provider-collected samples remain the preferred method, the ACS acknowledges that access to healthcare and comfort levels with pelvic exams can be barriers for some individuals. Self-collection offers a more accessible and private alternative, potentially increasing screening rates, particularly among those who are under- or un-screened.
Follow-Up and Screening Intervals
The frequency of screening depends on the type of test used and how the sample was collected. Individuals who receive HPV primary testing or co-testing with provider-collected samples and have normal results should be screened again in five years. Those who self-collect samples for HPV testing and have normal results should return for screening in three years. A Pap test alone, with normal results, requires repeat screening in three years. It’s significant to note that anyone with abnormal results will likely require more frequent monitoring.
The ACS also clarifies when screening can be stopped. Individuals who have had a decade of normal results – either negative HPV tests at ages 60 and 65, or three consecutive negative Pap tests, with the last one at age 65 – can discontinue screening. This reflects the decreasing risk of developing cervical cancer later in life, provided prior screening has been consistent and normal.
The Impact of Screening on Cervical Cancer Rates
Cervical cancer is a preventable disease, and widespread screening has dramatically reduced its incidence in the United States. Approximately 14,000 cases of cervical cancer are diagnosed annually in the U.S., resulting in over 4,000 deaths, according to the ACS. However, the disease progresses slowly, allowing for detection and treatment before it becomes life-threatening. In the U.S., screening has reduced cervical cancer cases by more than half since the mid-1970s.
Despite this progress, over half of cervical cancer diagnoses occur in individuals who have never been screened or who are infrequently screened. This highlights the importance of increasing access to screening and addressing barriers to participation. The new ACS guidelines, with their emphasis on HPV testing and self-collection, aim to address these challenges.
The expanded options for screening – including testing at primary care offices, urgent care clinics, mobile clinics, and even pharmacies, in addition to at-home self-collection – are designed to make it easier for more people to get tested. This is particularly beneficial for those who lack access to a gynecologist or feel uncomfortable with traditional pelvic exams. “These updated recommendations will support to improve compliance with screening and reduce the risk of cervical cancer,” explained Dr. Robert Smith, senior vice president, early cancer detection science at the American Cancer Society. He added that the development of self-collection tools will “broaden access to screening.”
Disclaimer: This article provides general information about cervical cancer screening and should not be considered medical advice. Please consult with a healthcare professional to determine the best screening schedule for your individual needs and risk factors.
The USPSTF is expected to release its updated recommendations in the coming months, which may further refine screening guidelines. Individuals should stay informed about these changes and discuss them with their healthcare providers. Regular screening remains the most effective way to prevent cervical cancer and protect your health.
Have questions about the new ACS guidelines or your own cervical cancer screening schedule? Share your thoughts in the comments below, and please share this article with anyone who might find it helpful.
